晚期惰性淋巴瘤的无化疗初始治疗具有持久疗效且毒性低:北欧淋巴瘤组两项试验的10年以上随访结果
北欧淋巴瘤组两项随机试验纳入321例惰性淋巴瘤患者(84%为滤泡性淋巴瘤),一线接受利妥昔单抗单药或联合干扰素α-2a无化疗方案。中位随访10.6年,73%存活,36%从未需要化疗,无化疗方案长期安全性良好。
要点
- 中位随访10.6年,73%患者存活,36%从未需要化疗。
- 惰性淋巴瘤一线无化疗方案长期疗效持久且无重大安全问题。
- 24个月内需新治疗的FL患者10年生存率59%,较长缓解者81%。
核心结论
- 约三分之一的症状性惰性淋巴瘤患者(FL为30%,非FL为23%)在无化疗一线利妥昔单抗后长期无需新治疗。
- 整个队列10年生存率优异且无重大安全问题,提示大多数患者可安全延迟化疗。
研究设计与样本
- 北欧淋巴瘤组两项随机试验的横断面随访研究,纳入321例惰性淋巴瘤患者(84%为FL),分别于1998至1999年和2002至2008年入组。
- 所有患者一线接受一或两个周期利妥昔单抗375 mg/m2每周四次输注,其中148例随机加用干扰素α-2a。
主要发现
- 随访结束时73%患者存活,随机分组后中位随访10.6年。
- 36%的患者(FL为38%)从未需要化疗。
- FL患者中24个月内因早期疾病进展需新治疗者10年生存率为59%,而缓解更持久者为81%。
- 干扰素未显示改善长期结局。
- 20%的患者(每人年2.4%)诊断转化,FL为18%;12%发现额外恶性肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For indolent lymphoma, the optimal timing, sequence, and choice of therapeutic regimens remain a matter of debate. In two Nordic Lymphoma Group randomized trials, symptomatic or clearly progressing patients were treated first line with a rituximab-containing regimen without chemotherapy. The purpose of this study was to assess long-term survival, risk of transformation, and need of new therapies. METHODS: Data were collected at cross-sectional follow-up for 321 patients with indolent lymphoma (84% with follicular lymphomas [FL]) included in one of two Nordic Lymphoma Group trials (accrual 1998 to 1999 and 2002 to 2008). All patients received first-line therapy with one or two cycles of four weekly infusions of rituximab 375 mg/m2, and 148 were randomly allocated to the addition of interferon alfa-2a. Follow-up data were retrieved from initial trial databases and medical records on repeated clinical evaluations. RESULTS: At the end of follow-up, 73% of patients were alive, with a median follow-up after random assignment of 10.6 years. Among all, 36% (38% with FL) had never needed chemotherapy. For patients with FL who required new therapy within 24 months because of early disease progression, the 10-year survival rate was 59% versus 81% for those with longer remission. Interferon was not shown to improve long-term outcome. Transformation was diagnosed in 20% of all patients (2.4% per person-year) and in 18% with FL. An additional malignancy was found in 12%. CONCLUSION: Approximately one third of patients with symptomatic indolent lymphoma (30% with FL, 23% without FL) did not need new therapy in the long term after first-line rituximab without chemotherapy. In the entire cohort, 10-year survival was excellent with no major safety issues, which suggests that chemotherapy can be delayed safely in the majority of patients.
引用
- Lockmer S, Østenstad B, Hagberg H, et al. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. J Clin Oncol. 2018. PMID: 30285560. doi:10.1200/JCO.18.00262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。